GT Biopharma, Inc. GTBP
Set alert
5.32 USD -0.28 -5.00%
At close · Oct 30
5.58 +0.26 +4.82%
After hours · Oct 30, 7:56 PM ET
5.32 Day range 5.54
0.554 52-week range 20.42
- YTD
- +577.71%
- 1 year
- +747.13%
- Open
- 5.47
- Prev close
- 5.60
- Mkt cap
- 10.96M
- Vol
- 20.27K
- Avg vol
- 64.76K
- EPS
- -147.50
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.32
- High
- 5.54
- Forward P/E
- -0.26
- Beta
- 0.57
- Short ratio
- 0.71
- Inst. own
- 67.52%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Apr 4, 2024
- 50-d avg
- 2.76
- 200-d avg
- 3.00
- 1y target
- 11.00
2Y chart
Events in this range
- Nov 14, 2024Earnings: -1.53; estimate 0; surprise —%
- Dec 2, 2024Rating: Roth MKM · — → Buy
- Sep 8, 2026Split: 1 for 25
Signals (92)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 22, 2026 | 1 week ago |
| SMA: Bearish | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 12, 2026 | 2 weeks ago |
| MACD: Sell Signal | Sep 24, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| RSI: Overbought | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 11, 2026 | 1 month ago |
| RSI: Oversold | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 4, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 7, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 6, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 25, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 17, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 16, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 9, 2026 | 4 months ago |
| SMA: Bullish | May 19, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| SMA: Bullish | May 14, 2026 | 5 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| RSI: Oversold | Apr 24, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 8, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 2, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 31, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 20, 2026 | 7 months ago |
| SMA: Bearish | Feb 25, 2026 | 8 months ago |
| RSI: Overbought | Jan 27, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 22, 2026 | 9 months ago |
| SMA: Bullish | Jan 2, 2026 | 10 months ago |
| RSI: Overbought | Jan 2, 2026 | 10 months ago |
| MACD: Buy Signal | Dec 17, 2025 | 10 months ago |
| SMA: Bullish | Dec 16, 2025 | 10 months ago |
| SMA: Bearish | Dec 3, 2025 | 11 months ago |
| MACD: Sell Signal | Dec 3, 2025 | 11 months ago |
| SMA: Bullish | Nov 21, 2025 | 11 months ago |
| SMA: Bearish | Nov 17, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 7, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 6, 2025 | 12 months ago |
| RSI: Oversold | Sep 29, 2025 | 1 year ago |
| RSI: Oversold | Sep 17, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 5, 2025 | 1 year ago |
| RSI: Oversold | Aug 19, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 14, 2025 | 1 year ago |
| RSI: Oversold | Aug 14, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 8, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 31, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 29, 2025 | 1 year ago |
| SMA: Bearish | Jul 7, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 3, 2025 | 1 year ago |
| RSI: Overbought | Jun 26, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 16, 2025 | 1 year ago |
| RSI: Overbought | Jun 11, 2025 | 1 year ago |
| RSI: Overbought | May 23, 2025 | 1 year ago |
| SMA: Bullish | May 21, 2025 | 1 year ago |
| MACD: Buy Signal | May 21, 2025 | 1 year ago |
| MACD: Sell Signal | May 13, 2025 | 1 year ago |
| SMA: Bullish | May 6, 2025 | 1 year ago |
| SMA: Bullish | Apr 30, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 28, 2025 | 1 year ago |
| SMA: Bearish | Apr 16, 2025 | 1 year ago |
| SMA: Bullish | Apr 15, 2025 | 1 year ago |
| SMA: Bearish | Apr 11, 2025 | 1 year ago |
| SMA: Bullish | Apr 10, 2025 | 1 year ago |
| SMA: Bearish | Apr 9, 2025 | 1 year ago |
| SMA: Bullish | Apr 8, 2025 | 1 year ago |
| SMA: Bearish | Apr 7, 2025 | 1 year ago |
| SMA: Bullish | Apr 1, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 24, 2025 | 1 year ago |
| SMA: Bullish | Mar 21, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 21, 2025 | 1 year ago |
| SMA: Bearish | Mar 20, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 20, 2025 | 1 year ago |
| SMA: Bullish | Mar 7, 2025 | 1 year ago |
| SMA: Bearish | Mar 6, 2025 | 1 year ago |
| SMA: Bullish | Mar 5, 2025 | 1 year ago |
| SMA: Bearish | Feb 26, 2025 | 1 year ago |
| SMA: Bullish | Feb 25, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 5, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 13, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 24, 2024 | 1 year ago |
| RSI: Oversold | Dec 19, 2024 | 1 year ago |
Key statistics
- Market cap
- 6.28M
- Enterprise value
- -2.72M
- Trailing P/E
- 0.00
- Forward P/E
- -0.26
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.52
- EPS (TTM)
- -7.39
- Beta
- 0.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -8.04M
- Total cash
- 9.25M
- Total debt
- 0
- Return on equity
- -131.48%
- Shares outstanding
- 2.23M
- Short % of float
- 0.81%
- 50-day average
- 2.76
- 200-day average
- 3.00
Analyst view
Consensus: none
Price target (mean) 11.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Apr 4, 2024
Expected Apr 4, 2024. Consensus EPS estimate 0.00.
Financials — quick view
GTBP Revenue — quarterly 0
GTBP Net income — quarterly -4.52M
GTBP EPS — quarterly -3.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -1.53 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -2.24 | — | — |
| May 15, 2024 | Mar 1, 2024 | -2.70 | -2.12 | +0.58 | +21.48% |
| Apr 4, 2024 | Dec 1, 2023 | -2.70 | — | — | — |
| Nov 1, 2023 | Sep 1, 2023 | -3.00 | -1.80 | +1.20 | +40.00% |
| Aug 7, 2023 | Jun 1, 2023 | -3.00 | -2.70 | +0.30 | +10.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2024 | Roth MKM | init | — | Buy |
About GT Biopharma, Inc.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- gtbiopharma.com
News
- GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
- EXCLUSIVE: GT Biopharma Announces Potential New Indication for GTB-5550, A B7-H3-Targeted Natural Killer Cell Engager, For Multiple Myeloma; FDA Clearance Under Investigator Sponsored Trial Protocol
- EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy
- 12 Health Care Stocks Moving In Monday's Intraday Session
- GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy Transcript
- 12 Health Care Stocks Moving In Friday's Intraday Session
- GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
Your note
Sign in to keep a note on GTBP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BREEN MICHAEL MARTIN | Chief Executive Officer | Stock Award(Grant) | Aug 10, 2023 | 856,218 |
| OHRI MANU | Chief Financial Officer | Stock Award(Grant) | Aug 10, 2023 | 350,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| DekaBank Deutsche Girozentrale | 51.69% | 1,154,867 | 3.25M | Sep 29, 2024 |
| Bank of Montreal /CAN/ | 1.34% | 29,872 | 83.94K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.67% | 15,041 | 42.27K | Sep 29, 2024 |
| Vanguard Group Inc | 0.47% | 10,504 | 29.52K | Sep 29, 2024 |
| Wells Fargo & Company | 0.45% | 10,013 | 28.14K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.45% | 10,105 | 28.39K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.50% | 11,201 | 31.47K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.47% | 10,504 | 29.52K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.10% | 2,196 | 6.17K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 1,152 | 3.24K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 255 | 716 | Oct 30, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 3 | 8 | Aug 30, 2024 |